

wherein

X and Z each represent CH or N;

$R^1$ ,  $R^2$ , and  $R^3$ , which may be the same or different, represent a hydrogen atom,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl, nitro, or amino, which  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy,  $C_{2-6}$  alkenyl, and  $C_{2-6}$  alkynyl are optionally substituted by a halogen atom; hydroxyl;  $C_{1-4}$  alkoxy;  $C_{1-4}$  alkoxy carbonyl; amino on which one or two hydrogen atoms are optionally substituted by  $C_{1-4}$  alkyl optionally substituted by hydroxyl or  $C_{1-4}$  alkoxy; group  $R^{12}R^{13}N-C(=O)-O-$  wherein  $R^{12}$  and  $R^{13}$ , which may be the same or different, represent a hydrogen atom or  $C_{1-4}$  alkyl which alkyl is optionally substituted by hydroxyl or  $C_{1-4}$  alkoxy; or group  $R^{14}-(S)_m-$  wherein  $R^{14}$  represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group optionally substituted by  $C_{1-4}$  alkyl and m is 0 or 1;


$R^4$  represents a hydrogen atom;

$R^5$ ,  $R^6$ ,  $R^7$ , and  $R^8$ , which may be the same or different, represent a hydrogen atom, a halogen atom,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C_{1-4}$  alkylthio, nitro, or amino, provided that  $R^5$ ,  $R^6$ ,  $R^7$ , and  $R^8$  do not simultaneously represent a hydrogen atom;

$R^9$  and  $R^{10}$ , which may be the same or different, represent a hydrogen atom,  $C_{1-6}$  alkyl, or  $C_{1-4}$  alkyl carbonyl, the alkyl portion of which  $C_{1-6}$  alkyl or  $C_{1-4}$  alkyl carbonyl is optionally substituted by a halogen atom;  $C_{1-4}$  alkoxy; amino which is optionally substituted by  $C_{1-4}$  alkyl optionally substituted by  $C_{1-4}$  alkoxy; or a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group; and

B<sup>1</sup> R<sup>11</sup> represents C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, or C<sub>2-6</sub> alkynyl (which C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, and C<sub>2-6</sub> alkynyl each are optionally substituted by a halogen atom or C<sub>1-6</sub> alkoxy), or R<sup>15</sup>-(CH<sub>2</sub>)<sub>n</sub>- wherein n is an integer of 0 to 4 and R<sup>15</sup> represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group which is optionally substituted by a halogen atom, C<sub>1-6</sub> alkyl, or C<sub>1-6</sub> alkoxy and is optionally condensed with another saturated or unsaturated three- to seven-membered carbocyclic ring or heterocyclic ring to form a bicyclic ring.

B<sup>2</sup> 5. (Amended) A compound represented by formula (Ia) or a pharmaceutically acceptable salt or solvate thereof:



wherein

X represents CH or N;

R<sup>21</sup> and R<sup>22</sup>, which may be the same or different, represent unsubstituted C<sub>1-6</sub> alkoxy or group R<sup>31</sup>-(CH<sub>2</sub>)<sub>p</sub>-O- wherein R<sup>31</sup> represents a halogen atom, hydroxyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkoxycarbonyl, amino on which one or two hydrogen atoms are optionally substituted by C<sub>1-4</sub> alkyl optionally substituted by hydroxyl or C<sub>1-4</sub> alkoxy, group R<sup>12</sup>R<sup>13</sup>N-C(=O)-O- wherein R<sup>12</sup> and R<sup>13</sup>, which may be the same or different, represent a hydrogen atom or C<sub>1-4</sub> alkyl which alkyl is optionally substituted by hydroxyl or C<sub>1-4</sub> alkoxy, or group R<sup>14</sup>-(S)<sub>m</sub>- wherein R<sup>14</sup> represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group optionally substituted by C<sub>1-4</sub> alkyl and m is 0 or 1; and p is an integer of 1 to 6;

B<sup>2</sup>  
R<sup>23</sup>, R<sup>24</sup>, R<sup>25</sup>, and R<sup>26</sup>, which may be the same or different, represent a hydrogen atom, a halogen atom, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, nitro, or amino, provided that R<sup>23</sup>, R<sup>24</sup>, R<sup>25</sup>, and R<sup>26</sup> do not simultaneously represent a hydrogen atom;

R<sup>27</sup> and R<sup>28</sup>, which may be the same or different, represent a hydrogen atom, C<sub>1-6</sub> alkyl, or C<sub>1-4</sub> alkylcarbonyl, the alkyl portion of which C<sub>1-6</sub> alkyl or C<sub>1-4</sub> alkylcarbonyl is optionally substituted by a halogen atom; C<sub>1-4</sub> alkoxy; amino which is optionally substituted by C<sub>1-4</sub> alkyl optionally substituted by C<sub>1-4</sub> alkoxy; or a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group; and

R<sup>29</sup> represents C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, or C<sub>2-6</sub> alkynyl (which C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, and C<sub>2-6</sub> alkynyl each are optionally substituted by a halogen atom or C<sub>1-4</sub> alkoxy), or R<sup>32</sup>-(CH<sub>2</sub>)<sub>q</sub>- wherein q is an integer of 0 to 4 and R<sup>32</sup> represents a saturated or unsaturated six-membered carbocyclic or heterocyclic group which is optionally substituted by a halogen atom, C<sub>1-4</sub> alkyl, or C<sub>1-4</sub> alkoxy and is optionally condensed with another saturated or unsaturated five- or six-membered carbocyclic ring or heterocyclic ring to form a bicyclic ring.

B<sup>3</sup>  
51. (Twice Amended) A method for treating a disease selected from the group consisting of malignant tumor, diabetic retinopathy, chronic rheumatism, psoriasis, and atherosclerosis, comprising the step of administering an effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier, to mammals.

Please add the following claims.

B<sup>4</sup>  
--53. (New) The method of claim 51, wherein the disease is Kaposi's sarcoma.  
54. (New) The compound according to claim 1, wherein R<sup>1</sup> represents a hydrogen atom and R<sup>2</sup> and R<sup>3</sup> represent unsubstituted C<sub>1-4</sub> alkoxy.

55. (New) The compound according to claim 1, wherein  $R^5$ ,  $R^7$ , and  $R^8$  represent a hydrogen atom and  $R^6$  represents a chlorine atom.

B4 56. (New) The compound according to claim 1, wherein  $R^{14}$  represents a saturated or unsaturated five- or six-membered carbocyclic or heterocyclic group.

57. (New) The compound according to claim 1, wherein  $R^{15}$  represents a saturated or unsaturated five- or six-membered carbocyclic or heterocyclic group.

58. (New) The compound according to claim 1, wherein  $R^1$  represents a hydrogen atom,  $R^2$  and  $R^3$  represent unsubstituted  $C_{1-4}$  alkoxy,  $R^5$ ,  $R^7$ , and  $R^8$  represent a hydrogen atom,  $R^6$  represents a chlorine atom,  $R^9$  and  $R^{10}$  represent a hydrogen atom, and  $R^{11}$  represents  $R_{15}-(CH_2)_n$ - wherein  $n$  represents 0 (zero) and  $R_{15}$  represents a saturated or unsaturated five- or six-membered carbocyclic or heterocyclic group.

59. (New) The compound according to claim 1, which is N-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-N'-propylurea.—

#### SUPPORT FOR THE AMENDMENTS

Claims 1 and 5 have been amended for clarity. Newly-added Claim 53 is supported by original Claim 51. The amendment to Claim 51 and newly added Claims 54-59 are supported by the specification at pages 1-200, especially pages 4-6 and 91. No new matter is believed to have been added to this application by these amendments.

#### REMARKS

Claims 1-48 and 51-59 are pending. Favorable reconsideration is respectfully requested.